Immune Pharmaceuticals Company Profile (NASDAQ:IMNP)

About Immune Pharmaceuticals (NASDAQ:IMNP)

Immune Pharmaceuticals logoImmune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $15.1 million
  • Outstanding Shares: 6,564,000
Average Prices:
  • 50 Day Moving Avg: $2.19
  • 200 Day Moving Avg: $0.70
  • 52 Week Range: $2.14 - $12.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 13.53
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.07 per share
  • Price / Book: 1.11
  • EBIDTA: ($16,860,000.00)
  • Return on Equity: -291.26%
  • Return on Assets: -64.25%
  • Debt-to-Equity Ratio: 0.17%
  • Current Ratio: 0.07%
  • Quick Ratio: 0.07%
  • Average Volume: 1.93 million shs.
  • Beta: 1.75
  • Short Ratio: 4.18

Frequently Asked Questions for Immune Pharmaceuticals (NASDAQ:IMNP)

What is Immune Pharmaceuticals' stock symbol?

Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."

How were Immune Pharmaceuticals' earnings last quarter?

Immune Pharmaceuticals Inc (NASDAQ:IMNP) released its quarterly earnings data on Monday, August, 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). View Immune Pharmaceuticals' Earnings History.

Where is Immune Pharmaceuticals' stock going? Where will Immune Pharmaceuticals' stock price be in 2017?

1 equities research analysts have issued twelve-month target prices for Immune Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Immune Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Immune Pharmaceuticals.

Are investors shorting Immune Pharmaceuticals?

Immune Pharmaceuticals saw a increase in short interest in April. As of April 28th, there was short interest totalling 750,273 shares, an increase of 35.8% from the April 13th total of 552,499 shares. Based on an average daily trading volume, of 2,183,226 shares, the short-interest ratio is currently 0.3 days. Currently, 8.5% of the shares of the company are short sold.

Who are some of Immune Pharmaceuticals' key competitors?

Who owns Immune Pharmaceuticals stock?

Immune Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (75.91%). Company insiders that own Immune Pharmaceuticals stock include Daniel Gedeon Teper, Daniel Kazado, Monica E Luchi and Rene Pierre Azria. View Institutional Ownership Trends for Immune Pharmaceuticals.

Who bought Immune Pharmaceuticals stock? Who is buying Immune Pharmaceuticals stock?

Immune Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Immune Pharmaceuticals stock in the last two years include Daniel Gedeon Teper, Daniel Kazado, Monica E Luchi and Rene Pierre Azria. View Insider Buying and Selling for Immune Pharmaceuticals.

How do I buy Immune Pharmaceuticals stock?

Shares of Immune Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Immune Pharmaceuticals stock cost?

One share of Immune Pharmaceuticals stock can currently be purchased for approximately $2.30.

Analyst Ratings

Consensus Ratings for Immune Pharmaceuticals (NASDAQ:IMNP) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (30.43% upside)

Analysts' Ratings History for Immune Pharmaceuticals (NASDAQ:IMNP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/3/2016FBR & CoReiterated RatingOutperform$3.00N/AView Rating Details
5/16/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
4/4/2016Roth CapitalReiterated RatingBuyN/AView Rating Details
6/11/2015MLV & Co.Initiated CoverageBuy$6.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Immune Pharmaceuticals (NASDAQ:IMNP)
Earnings by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)
Earnings History by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/15/2016Q2($0.13)($0.13)ViewN/AView Earnings Details
5/16/2016Q116($0.15)($0.17)ViewN/AView Earnings Details
3/30/2016Q4($0.16)($0.27)ViewN/AView Earnings Details
11/12/2015Q315($0.18)($0.33)$15.00 millionViewListenView Earnings Details
8/17/2015Q215($0.19)($0.12)ViewN/AView Earnings Details
5/18/2015Q1($0.20)($0.15)ViewN/AView Earnings Details
4/15/2015Q4 2014($0.37)($0.34)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.21)($0.27)ViewN/AView Earnings Details
5/21/2014Q1 2014($0.15)($0.35)ViewN/AView Earnings Details
4/10/2014Q4 2013($0.15)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Immune Pharmaceuticals (NASDAQ:IMNP)
Current Year EPS Consensus Estimate: $-0.62 EPS
Next Year EPS Consensus Estimate: $0.17 EPS


Dividend History for Immune Pharmaceuticals (NASDAQ:IMNP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Immune Pharmaceuticals (NASDAQ:IMNP)
Insider Ownership Percentage: 6.74%
Institutional Ownership Percentage: 2.18%
Insider Trades by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)
Insider Trades by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Daniel KazadoDirectorBuy76,503$0.19$14,535.57View SEC Filing  
12/16/2016Daniel KazadoDirectorBuy161,377$0.19$30,661.63View SEC Filing  
8/4/2016Daniel Gedeon TeperCEOBuy937,500$0.38$356,250.00View SEC Filing  
8/4/2016Daniel KazadoDirectorBuy666,667$0.45$300,000.15View SEC Filing  
8/4/2016Monica E LuchiCMOBuy777,778$0.45$350,000.10View SEC Filing  
1/26/2016Daniel Gedeon TeperCEOBuy42,000$0.59$24,780.00View SEC Filing  
1/19/2016Daniel Gedeon TeperCEOBuy44,200$0.57$25,194.00View SEC Filing  
1/12/2016Daniel Gedeon TeperCEOBuy39,400$0.62$24,428.00View SEC Filing  
1/5/2016Daniel Gedeon TeperCEOBuy62,000$0.81$50,220.00View SEC Filing  
12/7/2015Daniel Gedeon TeperCEOBuy65,400$0.76$49,704.00View SEC Filing  
12/7/2015Daniel KazadoDirectorBuy150,000$0.78$117,000.00View SEC Filing  
10/26/2015Daniel Gedeon TeperCEOBuy18,400$1.36$25,024.00View SEC Filing  
10/19/2015Daniel Gedeon TeperCEOBuy18,600$1.34$24,924.00View SEC Filing  
10/12/2015Daniel Gedeon TeperCEOBuy19,000$1.30$24,700.00View SEC Filing  
10/5/2015Daniel Gedeon TeperCEOBuy40,700$1.23$50,061.00View SEC Filing  
9/14/2015Rene Pierre AzriaDirectorBuy50,000$1.48$74,000.00View SEC Filing  
9/1/2015Daniel Gedeon TeperCEOBuy7,569$1.29$9,764.01View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Immune Pharmaceuticals (NASDAQ:IMNP)
Latest Headlines for Immune Pharmaceuticals (NASDAQ:IMNP)
DateHeadline logoImmune Pharmaceuticals Inc (IMNP) Short Interest Up 35.8% in April - May 13 at 7:12 AM logoShort Interest in Immune Pharmaceuticals Inc (IMNP) Expands By 6.4% - May 9 at 7:12 AM logoImmune Pharma (IMNP) Announces Private Placement of up to $3.4 ... - - May 4 at 6:03 PM logoImmune Pharmaceuticals Announces Private Placement of up to $3.4 Million - May 4 at 6:03 PM logoImmune Pharma (IMNP) Announces Corporate Restructuring, CEO to Resign - April 24 at 5:33 PM logoImmune Receives Nasdaq Letter - April 24 at 9:31 AM logoImmune Pharmaceuticals Announces Corporate Restructuring - April 24 at 9:30 AM logoImmune Pharma shares tumble 9% premarket as it unveils restructuring - April 24 at 9:30 AM logoSomewhat Favorable Media Coverage Somewhat Likely to Affect Immune Pharmaceuticals (IMNP) Stock Price - April 22 at 11:59 AM logoToday's Research Reports on Stocks to Watch: Aurinia ... - Yahoo Finance - April 22 at 8:10 AM logoToday's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Immune Pharmaceuticals - April 21 at 10:43 AM logoPre-Open Movers 04/20: (IMNP) (SCSS) (KCG) Higher; (PLXS) (WR) (PM) Lower (more...) - April 20 at 11:28 AM logoImmune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding License and Commercializion of Ceplene® in Latin America - April 20 at 11:28 AM logoImmune Pharma's stock rockets on heavy volume after license pact - April 20 at 11:28 AM logoWhy Immune Pharmaceuticals Shares Are Skyrocketing - April 20 at 11:28 AM logoImmune Pharmaceuticals (IMNP) Getting Somewhat Favorable Press Coverage, Report Shows - April 19 at 12:37 PM logoImmune Pharma (IMNP) to Trade on 1-for-20 Reverse Split-Adjusted Basis on April 13 - April 13 at 10:12 AM logoImmune Pharmaceuticals (IMNP) Given Daily Media Impact Score of -0.06 - April 13 at 8:56 AM logoImmune Pharmaceuticals Announces 1-for-20 Reverse Stock Split - April 12 at 9:11 AM logoIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E - March 23 at 6:30 PM logo9:57 am Immune Pharma announces that the Nasdaq Hearings Panel granted the Co's request for additional time to comply with Nasdaq listing requirements - March 13 at 5:45 PM logoIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Other Events - March 13 at 5:45 PM logoImmune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement - March 13 at 10:54 AM logo8:30 am Immune Pharma announces that it has broadened enrollment eligibility criteria based on the data reported from three patients that have completed treatment to date in its ten-patient open label study of Bertilimumab in the treatment - February 28 at 6:03 PM logoImmune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid - February 28 at 9:19 AM logoImmune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia - February 17 at 5:32 PM logoIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers - February 15 at 9:02 PM logoImmune Pharmaceuticals Appoints New Chairman of the Board of Directors - Yahoo Finance - January 28 at 12:55 AM logoImmune Pharma (IMNP) Enters Exclusive Sub-License Agreement with SATT Sud-Est - January 23 at 10:53 AM logoImmune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment - January 23 at 10:53 AM logoImmune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI - January 17 at 1:03 PM



Immune Pharmaceuticals (IMNP) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff